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Abstract
Introduction Continuous physiological monitoring devices
are often not available for monitoring high-risk neonates
in low-resource settings. Easy-t o-use, non-invasive,
multiparameter, continuous physiological monitoring
devices could be instrumental in providing appropriate
care and improving outcomes for high-risk neonates in
these low-resource settings.
Methods and analysis The purpose of this prospective,
observational, facility-based evaluation is to provide
evidence to establish whether two existing non-invasive,
multiparameter, continuous physiological monitoring
devices developed by device developers, EarlySense and
Sibel, can accurately and reliably measure vital signs
in neonates (when compared with verified reference
devices). We will also assess the feasibility, usability
and acceptability of these devices for use in neonates in
low-resource settings in Africa. Up to 500 neonates are
enrolled in two phases: (1) a verification and accuracy
evaluation phase at Aga Khan University—Nairobi and (2)
a clinical feasibility evaluation phase at Pumwani Maternity
Hospital in Nairobi, Kenya. Both quantitative and qualitative
data are collected and analysed. Agreement between the
investigational and reference devices is determined using
a priori-defined accuracy thresholds.
Ethics and dissemination This trial was approved by the
Aga Khan University Nairobi Research Ethics Committee
and the Western Institutional Review Board. We plan to
disseminate research results in peer-reviewed journals
and international conferences.
Trial registration number NCT03920761.

Introduction
In 2017 globally, 47% of all deaths in children
under 5 years of age occurred within the first
28 days of life, which translates to a neonatal
mortality rate of 18 deaths per 1000 live births
or 2.5 million newborn deaths.1Sub-Saharan
Africa bears the greatest burden of neonatal
mortality with an estimated 1 million newborn
deaths in 2017. Further efforts, especially
in African countries, are needed to push
progress towards achieving the Sustainable

Strengths and limitations of this study
►► This research consists of two phases, a verification

and accuracy evaluation phase and a clinical feasibility evaluation phase, and includes evaluation
invasive, mulof two novel, investigational, non-
tiparameter, continuous physiological monitoring
devices.
►► Verification of the reference devices is undertaken prior to initiating the accuracy evaluation of the
investigational devices to ensure the reference devices are robustly functional and to confirm their
within subject repeatability and accuracy compare
to standard clinical measurements for the relevant
parameters of interest.
►► Reliability information gathered from the reference
devices is used to determine specific a priori Go/No
Go criteria for each parameter of interest and each
investigational device.
►► As with all measurements, there is uncertainty inherent in the measurements from the reference
devices.
►► Inability to control for the characteristics and conditions of the participating neonates and to standardise the environment and context are both
strengths and limitations to interpreting the results.

Development Goal target of reducing global
neonatal mortality to 12 deaths per 1000
live births by 2030.2 Without accelerated
improvements, it is projected that 1.8 million
neonates will die in 2030.3 Innovations in
neonatal care, particularly technologies that
allow for early detection and intervention
for major morbidities, hold great promise
in helping to reduce current and projected
neonatal mortality rates.
Multiparameter continuous physiological
monitoring devices could be instrumental
in identifying neonates at risk. We can then
direct care provided for a neonate through
automatic interpretations of vital signs that
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Methods and analysis
Study design and setting
The primary objectives of this prospective, observational, facility-based research are: (1) to assess agreement
between repeat observations by the investigational device
and the reference device for each relevant measurement parameter of interest based on a priori-determined
accuracy threshold among neonates; (2) to compare
clinical event detection performance between the investigational device and the reference device and (3) to
determine whether the investigational device is feasible,
usable and acceptable to hospital administrators, healthcare providers and caregivers of neonates. Secondary
2

objectives include: (1) assessing diagnostic performance
for each relevant measurement parameter of interest
based on sensitivity, specificity, positive predictive value
and negative predictive value compared with the reference device; (2) determining the downtime performance
of the investigational device; (3) determining the alarm
rate (events/hour) and the number of true/false alarms
of the investigational device compared with the reference
device; (4) determining the delay time between the investigational device and the reference device in true events
and (5) determining the number of adverse device effects
(ADEs) and serious adverse events (SAEs) during the use
of the investigational device.
Beginning in June 2019 and anticipated to last approximately 18 months in Nairobi, Kenya, this research consists
of two phases: (1) a verification and accuracy evaluation
phase conducted at Aga Khan University-Nairobi (AKU-
N), a private, not-for-profit university teaching hospital
with a neonatal intensive care and high dependency units
and (2) a clinical feasibility evaluation phase conducted at
Pumwani Maternity Hospital (PMH), the largest referral
maternity hospital in sub-Saharan Africa with no neonatal
intensive care or high dependency units.
Study participants
Up to 500 neonates, corrected age of <28 days admitted
for routine observation and care at AKU-N and PMH are
recruited by trained study staff during routine intake and
screening procedures. To avoid potential selection bias,
neonates are screened for enrolment in a sequential
manner, as much as possible. Trained study staff assess the
neonate for all inclusion and exclusion criteria (table 1).
Final eligibility determination is dependent on the results
of the medical history, clinical examination, appropriate

Table 1

Eligibility criteria

Eligibility criteria
Inclusion criteria

Male or female neonate, corrected age
of <28 days
Willingness and ability of neonate’s
caregiver to provide informed consent
and to be available for follow-up for the
planned duration of the study

Exclusion criteria

Receiving mechanical ventilation or
continuous positive airway pressure
Skin abnormalities in the nasopharynx
and/or oropharynx
Contraindication to application of skin
sensors
Known arrhythmia
Any medical or psychosocial condition
or circumstance that, in the opinion of
the investigators, would interfere with
the conduct of the study or for which
study participation might jeopardise the
neonate’s health
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help identify critical events and determine if treatment is
sufficient or insufficient, ultimately improving newborn
outcomes.4 5 These devices would be most useful in low-
resource settings where the need for such technologies
is greatest. While continuous physiological monitoring
is standard of care in high-resource settings for those
who require it, the devices are expensive and require
specialised training to operate, making them unsuitable
for application in low-resource settings. To address these
barriers, it is necessary to explore how these technologies
can be adapted and/or optimised for use in low-resource
settings. Ideally, the devices should be low cost, operator-
independent, non-invasive and highly efficient in diagnostic performance and operator workload. This requires
development of a robust testing platform that appropriately mimics conditions common in African newborn
or neonatal intensive care units that would allow these
type of technologies to be evaluated for feasibility and
performance.
The Evaluation of Technologies for Neonates in Africa
(ETNA) project was conceived with the goal of advancing
and supporting development, as well as evaluation, of
select devices for use in neonates in low-resource settings.
By establishing a testing platform in an African site,
and working collaboratively with partners with expertise in device development and evaluation and neonatal
and child health, the project seeks to boost development and optimisation of promising newborn care
devices that could be applied in low-
resource settings
in Africa.We acknowledge the many challenges involved
in implementing such devices in low-
resource settings
(eg, electricity and internet access, behavioural change
communication, etc), and the need to consider these
challenges carefully prior to introduction.The purpose
of this initial research is to produce evidence regarding
the performance of two existing non-invasive, multiparameter, continuous physiological monitoring devices
developed by device developers, Early Sense and Sibel,
to accurately and reliably measure vital signs in neonates
(when compared with verified reference devices) and to
assess the feasibility, usability and acceptability of these
devices for use in neonates in a low-resource setting in
Africa.

Open access

Investigational devices
Developed by Israeli-
based EarlySense since 2009, the
Insight system, released in 2016, is a contact-free monitoring system composed of a small piezoelectric sensor
pad that can be placed under the patient’s mattress, and
is designed to measure and record a patient’s heart rate
(HR), respiratory rate (RR), motion and sleep status.6
Information from the sensor pad, in combination with
Early Sense’s artificial intelligence analytics, is transmitted
to a monitor to provide alert indications and vital sign
trends to healthcare providers so that they can monitor
changes in a patient’s condition. Currently in use in
hospitals, rehabilitative centres, and nursing homes to
measure vital signs in adults and children above 10 kg,
the device is modified for use in neonates as part of this
study. The adult device received regulatory approval from
the US Federal Drug Administration and has a Conformité Européene mark for continuous and contactless
measurement of HR, RR and motion. No adverse events
(AEs) related to the system have been reported during 10
years of monitoring.
Developed in 2019, the advanced neonatal epidermal
(ANNE) system from Sibel, a technology company spun
out from the Center of Bio-
Integrated Electronics at
Northwestern University in the USA, is a system of two
time-linked soft and flexible sensors designed to measure
and monitor vital signs including HR, RR, oxygen saturation (SpO2) and skin temperature in neonates.7 The chest
sensor couples to the skin via a hypoallergenic, biocompatible hydrogel adhesive optimised for reduced peel
force on removal, and the limb unit couples via a latex-
free soft fabric wrap adaptable to a range of foot sizes
and anatomies. Information from the sensors is wirelessly
transmitted to a monitor or mobile device via encrypted
Bluetooth for real-
time streaming from a customised
mobile software application as well as onboard memory
storage on the sensors themselves. The device has been
validated in more than 50 neonates in a neonatal care
unit without AEs.
Reference devices
We are employing the Masimo Rad-97 and the Spengler
Tempo Easy Bleu devices as our reference devices for this
Ginsburg AS, et al. BMJ Open 2020;10:e035184. doi:10.1136/bmjopen-2019-035184

study. The Masimo Rad-97 provides continuous physiological monitoring of HR, RR, SpO2 and capnography.
The Spengler Tempo Easy Bleu non-
contact infrared
thermometer predicts core body temperature from the
temporal artery temperature.
Study procedures
Following completion of screening for eligibility, a study
comprehension checklist and written informed consent,
study staff perform procedures (online supplementary
appendix 1: Schedule of study procedures and evaluations) according to the most recently approved version
of the protocol (current V.1.1, 18 June 2019). Enrolled
neonates are assigned a participant identification
number; information is collected on sociodemographic
characteristics, current clinical status, medical history,
medications; and a physical examination is performed.
Prior to initiating the accuracy evaluation of each investigational device, verification of the reference devices,
Masimo Rad-97 and Tempo Easy Bleu, is undertaken
at AKU-N to ensure they are robustly functional and to
confirm their within subject repeatability and accuracy
compared with standard clinical measurements (eg,
manual, bedside electrocardiography) for the relevant
parameters of interest. Neonates enrolled during reference device verification continue to receive local standard
of care while being observed intermittently for vital signs
collection for a minimum of 1 hour using the Masimo
Rad-97 and intermittent measurements with the Tempo
Easy Bleu. Observations may include video recordings
of the neonate and the Masimo Rad-97 reference device
monitor for later review to facilitate manual count observations. The reference device measurements will be
compared with manual measurements, clinical monitor
observations and video-assisted observations. Reliability
information gathered from the reference devices is used
to determine specific Go/No Go criteria for each parameter and each investigational device. Further evaluation
of each investigational device only proceeds should these
criteria be met.
Enrolment in the accuracy evaluation of the investigational devices, EarlySense Insight system and Sibel ANNE
system, is initiated at AKU-N to formally assess their accuracy compared with the verified reference device using
repeated observations. Enrolled neonates continue to
receive local standard of care while having vital signs
collected from the reference device as well as one or both
of the investigational devices. Placement of the investigational and reference devices is done in a manner so as
not to interfere with the neonate’s clinical care. Observations are collected for a minimum of 1 hour and potentially for the entire duration of their stay in the hospital.
Observations may consist of videotaping and/or taking
photos of the neonate during the observation period
after obtaining informed consent from the caregiver. Any
photos or videos takes are identified by patient identification number only and stored on a secure server until the
analyses are completed and destroyed following analyses.
3
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understanding of the study by the caregiver and completion of the written informed consent process. A neonate
may be enrolled to the study more than once as long as
they meet the eligibility criteria and the caregiver(s) is
willing to have the neonate participate.
For the feasibility, usability and acceptability assessment,
hospital administrators and study healthcare providers are
enrolled if they are 18 years or older, involved in or aware
of the ETNA study, and have provided written informed
consent. Caregivers may be enrolled if they are 18 years
or older, have a neonate enrolled in the study and are
willing to participate in an in-depth interview as well as
direct observation while their neonate is on or attached
to the investigational device(s).

Open access
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of all participating neonates, including assessing for and
reporting ADEs (eg, erythema or oedema at the investigational or reference device sensor site) and/or SAEs (ie,
any ADE resulting in permanent skin damage). Any ADEs
or SAEs will be treated until resolution or stabilisation,
and may require removal of devices and withdrawal of the
neonate from the study if necessary. If withdrawn by the
study team, any enrolled neonate who completes at least
1 hour of monitoring will be included in the analysis and
results.
Qualitative substudy
After written informed consent is received from the study
participants, a mixed-methods evaluation and data collection through audio-
recorded semistructured in-
depth
interviews and direct observations are conducted by
trained qualitative study staff to assess the feasibility,
usability and acceptability of the investigational devices
for monitoring of neonates in an African setting. Questions around technology use, experience with continuous
monitoring devices and specific to each investigational
and reference device will be asked and their use observed.
All hospital administrators and study healthcare providers
may be involved in this portion of the study. Caregivers
with a neonate enrolled in the study may also be asked if
they would like to participate in the qualitative portion of
the study.
Sample size
A total of up to 500 neonates are enrolled. For the veriN, up to 30
fication of the reference devices at AKU-
neonates are enrolled. Once this initial testing and data
collection of the reference devices are complete, for the
accuracy evaluation phase at AKU-N, up to 120 neonates
per investigational device are enrolled. Sample size estimates for the verification of the reference devices and the
accuracy evaluation phase are based on the CIs desired
for the limits of agreement. Sample sizes of 100–200
typically provide tight CIs. A sample of 20 neonates with
10 replications per neonate per device per round of
testing provides limits of agreement with 95% CIs±0.24,
calculated as 1.96*sqrt(3/ (20*10)), times the SD of the
paired differences. The paired differences are from the
reference device and manual measurements obtained
during verification of the reference device, and from
the reference device and investigational device measurements obtained during the accuracy evaluation phase.
For the clinical feasibility evaluation phase at PMH, up
to 120 neonates per investigational device are enrolled.
The sample sizes for each phase have been selected to
maximise the amount of information collected within the
confines of the available resources.
For the feasibility, usability and acceptability assessment,
the total sample size includes all hospital administrators
and study healthcare providers willing to participate and
provide consent as well as up to 30 caregivers willing to
participate and provide consent study at each site.
Ginsburg AS, et al. BMJ Open 2020;10:e035184. doi:10.1136/bmjopen-2019-035184
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During the observation, clinical status and any activities
are updated and recorded including type and duration
of care activities (eg, feeding, diaper changes, bathing,
kangaroo mother care, etc), clinical procedures, interventions, therapies, laboratory tests, medications, environmental features and exposures during the hospitalisation.
The device placement, output and signal quality are also
monitored. In addition, the neonates are assessed for any
safety issues. Agreement between the investigational and
reference devices is determined using a priori-defined
accuracy thresholds. Thresholds are determined largely
based on repeated within and between subject observations during verification of the reference devices. This
is complemented by previously published international
standards where available, and clinical expert consensus
opinion as needed. Two a priori-determined thresholds
are determined: one lower threshold to allow the device
developer to optimise the device for retesting, and a
second higher threshold to allow the device to move on
to the clinical feasibility phase of testing. A maximum of
five rounds of testing and retesting are permitted for each
investigational device. Each round of testing or retesting
consists of using a cohort of 20 neonates. Should the
lower threshold not be reached for at least one parameter, no further testing of the investigational device is
performed. Thus, information collected during the accuracy evaluation along with the a priori-determined Go/
No Go criteria established during verification of the reference devices define which, if any, of the investigational
devices moves forward with additional rounds of testing
or into the clinical feasibility evaluation phase at PMH.
An investigational device advances to the clinical
feasibility evaluation phase once the agreement for the
measurement parameters of interest exceed the higher
accuracy threshold. Enrolment in the clinical feasibility
evaluation phase of the investigational devices occurs at
PMH up to 120 enrolled neonates who receive local standard of care while being monitored with the reference
device(s)and one or both of the investigational devices.
Observations are collected for a minimum of 1 hour and
involve measurement of vital signs via the investigational
and reference devices and monitoring for any critical
event (ie, low or high HR, RR or temperature or oxygen
desaturation and apnoea). Agreement between repeated
observations from the investigation a land reference
devices as well as diagnostic performance in clinical event
detection is evaluated. Additional performance metrics
such as alarm rates, alarm delays and uptime\downtime
are compared between the investigational and reference
devices. Participation in the study does not interfere with
or unnecessarily delay the clinical care of the neonates.
Throughout all phases of the research, the investigational devices are not used to inform clinical care. During
the clinical feasibility evaluation phase, ETNA site study
staff and hospital healthcare providers are blinded to
the data collected from the investigational devices to
prevent interference with clinical care. The study site
investigators are responsible for close safety monitoring

Open access

Data management
Primary data management activities, which include
deidentified investigational and reference device data
to-
end encryption with two-
factor
transfer using end-
authentication, data entry and validation, data cleaning,
database quality control and disaster recovery plans are
undertaken at the study site and are overseen by the
on-site data manager. Data review and analysis, oversight
and preparation of final study database is performed by
the investigators in collaboration with the study site. Data
are maintained and stored securely in databases hosted at
the study site throughout the study and for at least 5 years
after study closure. All data management activities are
in compliance with International Council on Harmonisation (ICH) GCP E6, sponsor organisation and institutional requirements for the protection of children and
confidentiality of personal and health information.
Outcomes
We hypothesise that the investigational device is accurate and reliable compared with the reference device for
each relevant measurement parameter of interest among
neonates and is feasible, usable and acceptable for use in
neonates in low-resource settings. The primary endpoint
and secondary endpoints are detailed in box 1.
Statistical analyses
Every second of data is automatically graded as optimal,
acceptable and unacceptable based on predefined rules
for each device and each measurement parameter of
Ginsburg AS, et al. BMJ Open 2020;10:e035184. doi:10.1136/bmjopen-2019-035184

Box 1

Study endpoints

Primary endpoints
►► Agreement of the relevant measurement parameters of interest be-

tween the investigational device and the reference device at each
observation.
►► Agreement of clinical event detection between the investigational
device and the reference device at each observation.
►► Feasibility, usability and acceptability of the investigational device
among hospital administrators and healthcare providers.
►► Acceptability of the investigational device among caregivers.
Secondary endpoints
►► Diagnostic performance of the investigational deviceto appropriately
identify the following critical events:
–– Low heart rate.
–– High heart rate.
–– Low respiratory rate.
–– High respiratory rate.
–– Oxygen desaturation.
–– Apnoea.
–– Low temperature.
–– High temperature.
►► Downtime duration of the investigational device.
►► Alarm rate (events/hour and ratio of false positives to missed critical
events of the investigational device’salarms compared with the reference device’s alarms.
►► Response time of the investigational device’s alarms compared with
the reference device’s alarms for critical events
►► Proportion of neonates with adverse device effects and serious adverse events resulting in skin damage.

interest according to the quality of the data for each
measurement parameter of interest. The Masimo Rad-97
provides a signal quality index that is used to determine
data quality for HR and SpO2. A custom algorithm has
been produced to determine the capnography signal
quality index. Each of the investigational devices also
provides a signal quality index. The quality thresholds
are determined following verification of the reference
devices. All comparisons are performed from observations between two devices (or a single device during verification). At least 10 observations of 60 s of optimal quality
data in each neonate, at least 5 min apart, are randomly
selected for each measurement parameter of interest
from the full recording. For the clinical feasibility evaluation phase, accuracy comparisons use optimal or acceptable data. At least 3 hours of recording to a maximum of
12 hours are used for the performance metrics such as
alarm rates, alarm delays and uptime\downtime.
The repeatability of the reference device parameter
estimates initially is assessed with the intraclass correlation coefficient (ICC). Additional training or standardisation of procedures is performed to ensure at least good
repeatability (ICC >0.7). This is followed by measuring
agreement between the repeated reference observations
and between the manual, clinical monitor and video-
assisted methods and the reference observations using
the methods described by Bland and Altman for replicated observations.8 The agreement is reported as a mean
5
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Data collection and quality assurance
Quantitative study data are collected by clinical study
staff using designated source documents as well as electronic or paper-based case report forms. Data are stored
and managed by a database developed via Research Electronic Data Capture, a secure web application. Continuous physiological data and event data are recorded from
the investigational and reference devices at least once a
second. All electronic data are collected wirelessly or via
a wired connection from the investigational and reference devices to a study laptop using custom software
applications. Qualitative study data are collected using
paper-based forms and audio recordings, which are subsequently transcribed for analysis.
Clinical research data, including data collected from
the investigational and reference devices, are maintained
through a combination of secure electronic data management system and physical files with restricted access to
ensure confidentiality. Two distinct study databases are
maintained separately: the primary study database and a
database with participating neonate’s personally identifiable information. To ensure accuracy and completeness,
data are routinely reviewed by the investigators through
quality assurance reviews, audits and evaluation of the
study safety and progress. Guideline for Good Clinical
Practice (GCP)/ISO 14155 compliance is followed to
ensure accurate, reliable and consistent data collection.

Open access
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Ethics and dissemination
Ethical approvals and consent
The study is conducted in accordance with the ICHGCP
and the Declaration of Helsinki 2008. The protocol and
other relevant study documents study were approved by the
Western Institutional Review Board 20 191 102 (Puyallup,
Washington, USA), and the Aga Khan University Nairobi
Research Ethics Committee 2019/REC-02 (v2)(Nairobi,
Kenya). Written informed consent is obtained in the local
language by trained study staff from all eligible neonate’s
caregivers and for the qualitative substudy, from participating hospital administrators, healthcare providers and
caregivers prior to enrolment. Potential participants will
have adequate time to ask questions and a comprehension checklist will be administered to ensure participant
understanding.
Possible risks
Caregivers may feel compelled to enrol in the study in
order to receive care for their neonate within a research
setting, which may be perceived as of a higher quality
than the standard of care. In order to minimise the risk
of coercion, during the informed consent process, study
staff emphasise that the neonate will receive the required
medical care whether enrolled in the study or not.
Other potential risks to study participation may include
those associated with the placement and attachment of
the investigational and reference devices, and delayed
medical management. Study staff are trained in the appropriate placement of investigational and reference devices’
sensors to minimise discomfort to the neonates as well as
to avoid interference with any assessment, treatment or
intervention necessary for clinical care. There is a potential risk of skin irritation with the ANNE sensor system
and neonates will be closely monitored and treated for
any AEs. Study staff are also trained in integrating study
procedures with clinical care and to always prioritise clinical care above study procedures. Extreme care is taken to
ensure that no necessary treatment is delayed to accommodate study procedures.
Dissemination
We plan to disseminate study results in peer-
reviewed
journals and international conferences, targeting those
involved in the clinical care of neonates in low-resource
settings as well as those who develop and advise on policies and guidelines in those settings.
Efforts towards rigorous protocol
Dedicated study staff trained in GCP, operation, use and
maintenance of the investigational and reference devices,
and study-specific procedures follow neonates enrolled in
the trial to assure the protocol and standard operating
procedures are followed and data are accurately collected.
Standardised study-
specific training, supervision and
oversight are undertaken to ensure quality, consistency
and harmonised trial procedures and implementation.
Regular monitoring is provided by the coinvestigators
Ginsburg AS, et al. BMJ Open 2020;10:e035184. doi:10.1136/bmjopen-2019-035184
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bias with 95% CIs and 95% limits of agreement. Graphical representation of the data is assessed with agreement plots, Clarke error grids and Polar plots to identify
extreme outliers and significant data trends.
In the accuracy evaluation, the root mean square
difference and ICC are calculated for each measurement
parameter of interest to compare the multiple repeated
observations between the investigational and reference
devices. The agreement between each investigational
device and reference device(s) is then calculated using
the methods described by Bland and Altman for replicated observations. The agreement is reported as a
mean bias with 95% CIs and 95% limits of agreement.
Graphical representation of the data is be assessed with
agreement plots, Clarke error grids and Polar plots to
identify extreme outliers, impact on clinical decisions,
and significant data trends. An a priori-defined accuracy
margin for agreement is used as a threshold value to
allow for decisions regarding proceeding to additional
testing.
In the clinical feasibility evaluation phase, agreement
between each investigational device and reference
device(s) is assessed as in the accuracy evaluation phase.
Event detection rates, alarm rates, alarm delays and
uptime/downtime are summarised with means, medians
SD and IQRs as appropriate. Summaries of sensitivity,
specificity, positive predictive values and negative predictive values comparing each measurement parameter of
interest in the investigational device(s) to the reference
device(s) are produced. Comparisons of binary events are
assessed using Cohen’s weighted Kappa and McNemar’s
test. The non-inferiority of alarm rates, alarm delays and
uptime/downtime are evaluated based on prespecified
thresholds.
Qualitative data are collected through in-depth interviews and/or semistructured questionnaires and analysed to assess feasibility, usability and acceptability of the
investigational devices among hospital administrators
and healthcare providers, and acceptability among caregivers of enrolled neonates. Questions that explore familiarity, knowledge, perceptions, attitudes and behaviours
regarding the devices are included. The qualitative data
are in narrative format and the results are descriptive.
The questionnaires are coded and analysed using a codebook with identified themes, including feasibility of using
each investigational device, barriers and facilitators to
use, and perceived value. Qualitative data analysis software is used to organise, code and analyse the qualitative
data in an iterative process. The study team starts by identifying an initial set of codes and themes based on the
categories from the interview guides. During the coding
process, attention is paid to identifying emergent issues
and themes that are added to the codebook and included
in the analysis. Responses from the interviews are coded
and discrepancies discussed and resolved for the final
analysis and theme identification.

Open access

Limitations and bias
Limitations to this study and potential sources of bias
include the sampling strategy, the uncertainty inherent
in the measurements from the reference devices, the
limited standardisation of time of day of recording and
the inability to control the conditions and standardise the
context. Because there is a large variation in the various
ages, weights, sizes, disease states, clinical presentations,
interventions received and conditions of the participating
neonates, it is not possible to control for all these variables. Likewise, the environment cannot be controlled,
does not allow for complete standardisation and may
introduce additional sources of bias. These limitations
may also be viewed as strengths.
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